These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12393643)

  • 1. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation.
    Hashimoto K; Matsumura I; Tsujimura T; Kim DK; Ogihara H; Ikeda H; Ueda S; Mizuki M; Sugahara H; Shibayama H; Kitamura Y; Kanakura Y
    Blood; 2003 Feb; 101(3):1094-102. PubMed ID: 12393643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site.
    Tsujimura T; Hashimoto K; Kitayama H; Ikeda H; Sugahara H; Matsumura I; Kaisho T; Terada N; Kitamura Y; Kanakura Y
    Blood; 1999 Feb; 93(4):1319-29. PubMed ID: 9949175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
    Lindblad O; Kazi JU; Rönnstrand L; Sun J
    Cell Mol Life Sci; 2015 Nov; 72(22):4399-407. PubMed ID: 26040420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.
    Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D
    Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.
    Kitayama H; Kanakura Y; Furitsu T; Tsujimura T; Oritani K; Ikeda H; Sugahara H; Mitsui H; Kanayama Y; Kitamura Y
    Blood; 1995 Feb; 85(3):790-8. PubMed ID: 7530509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
    Munugalavadla V; Sims EC; Borneo J; Chan RJ; Kapur R
    Blood; 2007 Sep; 110(5):1612-20. PubMed ID: 17483298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.
    Sun J; Mohlin S; Lundby A; Kazi JU; Hellman U; Påhlman S; Olsen JV; Rönnstrand L
    Oncogene; 2014 Nov; 33(46):5360-9. PubMed ID: 24213578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.
    Ning ZQ; Li J; Arceci RJ
    Blood; 2001 Jun; 97(11):3559-67. PubMed ID: 11369651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid rafts are required for Kit survival and proliferation signals.
    Jahn T; Leifheit E; Gooch S; Sindhu S; Weinberg K
    Blood; 2007 Sep; 110(6):1739-47. PubMed ID: 17554062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of c-KIT expression level and phosphatidylinositol 3-kinase activation in survival and proliferative responses of early myeloid cells.
    Young SM; Cambareri AC; Ashman LK
    Cell Signal; 2006 May; 18(5):608-20. PubMed ID: 16002264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.
    Piao X; Bernstein A
    Blood; 1996 Apr; 87(8):3117-23. PubMed ID: 8605325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.
    Ning ZQ; Li J; McGuinness M; Arceci RJ
    Oncogene; 2001 Jul; 20(33):4528-36. PubMed ID: 11494148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
    Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
    J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1.
    Piao X; Paulson R; van der Geer P; Pawson T; Bernstein A
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14665-9. PubMed ID: 8962111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
    Vempati S; Reindl C; Wolf U; Kern R; Petropoulos K; Naidu VM; Buske C; Hiddemann W; Kohl TM; Spiekermann K
    Clin Cancer Res; 2008 Jul; 14(14):4437-45. PubMed ID: 18628457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential.
    Gommerman JL; Sittaro D; Klebasz NZ; Williams DA; Berger SA
    Blood; 2000 Dec; 96(12):3734-42. PubMed ID: 11090054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
    Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
    Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells.
    Serve H; Hsu YC; Besmer P
    J Biol Chem; 1994 Feb; 269(8):6026-30. PubMed ID: 7509796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.